Bio-Rad snaps up antibody manufacturer in €53M cash deal

Bio-Rad Laboratories ($BIO) has snapped up AbD Serotec, a division of MorphoSys AG, for about €53 million ($70 million) in cash.

The Hercules, CA-based Bio-Rad, which makes and sells life science research and clinical diagnostic products, says the deal delivers a leading antibody manufacturer, with more than "15,000 antibodies, kits, and accessories."

AbD Serotec has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as other facilities in Germany and the U.S.

"We are pleased to have AbD Serotec join Bio-Rad," said Norman Schwartz, Bio-Rad president and CEO. "With AbD Serotec's comprehensive catalog of antibodies, we are able to offer our customers total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA, and cell sorting."

- here's the press release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.